GoodRx (NASDAQ:GDRX) Trading Up 8.2% – Should You Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX) shares traded up 8.2% during trading on Friday . The stock traded as high as $4.64 and last traded at $4.64. 979,573 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 1,444,092 shares. The stock had previously closed at $4.29.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. UBS Group lowered their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a report on Friday, August 16th. Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Citigroup decreased their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Finally, Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.86.

GoodRx Trading Up 14.2 %

The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The business’s 50-day moving average price is $6.22 and its 200 day moving average price is $7.32. The company has a market cap of $1.87 billion, a P/E ratio of -163.33, a P/E/G ratio of 3.12 and a beta of 1.39.

Insider Buying and Selling

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.17% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On GoodRx

Several large investors have recently modified their holdings of the stock. Barclays PLC grew its stake in GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares during the last quarter. Fortem Financial Group LLC bought a new stake in shares of GoodRx during the third quarter worth approximately $772,000. Geode Capital Management LLC grew its position in shares of GoodRx by 6.3% in the third quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock valued at $6,823,000 after purchasing an additional 58,610 shares during the last quarter. Pier Capital LLC bought a new position in shares of GoodRx during the third quarter worth approximately $3,259,000. Finally, EP Wealth Advisors LLC bought a new position in shares of GoodRx during the third quarter worth approximately $73,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.